{"version":"1.0","type":"link","title":"Risk-benefit stratification for immune checkpoint inhibitor therapy in head and neck cancer based on immune-related adverse events and treatment discontinuation using routine clinical indicators beyond PD-L1 expression.","author_name":"Kasahara K 외","author_url":"https://prs-insight.online/author/Kasahara%20K","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/166701","thumbnail_width":1200,"thumbnail_height":630}